MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jmii.2023.07.013

Медицинская библиотека · Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023

Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound.

Chen Guan-Jhou, Sun Hsin-Yun, Chang Sui-Yuan, Hsieh Szu-Min, Sheng Wang-Hui, Chuang Yu-Chung, Huang Yu-Shan, Lin Kuan-Yin, Liu Wen-Chun, Su Yi-Ching, Hung Chien-Ching

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Antiretroviral regimens containing a second-generation integrase strand-transfer inhibitor (INSTI) plus 2 nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) are the recommended therapy for people with HIV (PWH) who are antiretroviral-naïve or on stable antiretroviral therapy (ART) with viral suppression. Real-world data on the virologic effectiveness of co-formulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among PWH with virologic failure while receiving other ART remain sparse.

METHODS

We retrospectively reviewed the medical records of PWH who had viral rebound with plasma HIV RNA >1000 copies/mL and were switched to either dolutegravir combined with 2 NRTIs or BIC/FTC/TAF. The primary end point was re-achieving viral suppression within the first 48 weeks of switch. The association between NRTI-related resistance-associated mutations (RAMs) and virologic effectiveness was examined.

RESULTS

Seventy-nine PWH with viral rebound while receiving other antiretroviral regimens were included. Within the first 48 weeks of switch, the overall probability of re-achieving viral suppression was 79.7% (82.5% [33/40] and 76.9% [30/39] for BIC/FTC/TAF and dolutegravir-based regimens, respectively, p = 0.78). PWH with a higher CD4 lymphocyte count (adjusted odds ratio, per 100-cell/mm3 increase, 1.41; 95% confidence interval, 1.02-1.95) were more likely to re-achieve viral suppression. Among PWH switching to BIC/FTC/TAF who had pre-existing RAMs to NRTIs before switch, 14 of 15 (93.3%) successfully achieved viral suppression.

CONCLUSIONS

Switching to BIC/FTC/TAF and dolutegravir-based regimens could re-achieve viral suppression in four-fifth of the PWH who experienced viral rebound during treatment with other antiretroviral regimens. Pre-existing NRTI-related RAMs did not have adverse impact on the effectiveness of dolutegravir combined with 2 NRTIs or BIC/FTC/TAF.

Для цитирования: Chen Guan-Jhou, Sun Hsin-Yun, Chang Sui-Yuan, Hsieh Szu-Min, Sheng Wang-Hui, Chuang Yu-Chung, Huang Yu-Shan, Lin Kuan-Yin, Liu Wen-Chun, Su Yi-Ching, Hung Chien-Ching. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound.. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2023. DOI: 10.1016/j.jmii.2023.07.013.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.